Device Trial Radar · NCT07932912
Evaluation of Hyaluronic Acid Gel and Concentrated Growth Factor in Periodontal Therapy
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 1, 2023
Primary completion
Nov 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- Amina Fouad FaragAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: Periodontitis is a chronic inflammatory disease of the tooth-supporting tissues, resulting from an imbalance between the host immune response and periodontopathogenic bacteria. Minimally invasive non-surgical therapy (MINST) reduces soft-tissue trauma and preserves clot stability. Healing may be further enhanced by two adjuncts: high-molecular-weight hyaluronic acid (HA), which has anti-inflammatory and mucoadhesive properties, and concentrated growth factor (CGF), an autologous platelet concentrate. Vascular endothelial growth factor (VEGF) in gingival crevicular fluid (GCF) serves as a marker of inflammation, angiogenesis and healing. Aim: This study evaluated the clinical and biochemical outcomes of 0.8% HA gel and liquid CGF as adjuncts to MINST in stage II-III periodontitis. The primary outcome was clinical attachment level (CAL) gain at 6 months. Secondary outcomes were probing depth (PD), bleeding on probing (BoP), gingival index (GI), plaque index (PI) and GCF VEGF levels at 1, 3 and 6 months. Subjects and Methods: This three-arm, parallel-group randomized clinical trial included 66 systemically healthy non-smokers aged 20-40 years with stage II-III periodontitis and pockets of at least 5 mm. Patients were recruited at the Faculty of Dentistry, October 6 University, under ethics approval RECO6U/34-2023. A sample size of 22 per group was calculated with G\*Power (α = 0.05, power 80%, effect size 0.4). After an initial hygiene phase, patients whose full-mouth plaque and bleeding scores fell below 20% were randomized by computer-generated sequence into three groups. Group I received MINST alone. Group II received MINST plus 0.8% HA gel injected subgingivally and repeated after 4 weeks. Group III received MINST plus liquid CGF, prepared from about 9 mL of the patient's venous blood, injected subgingivally and repeated after 4 weeks. MINST was performed under local anesthesia with 5× loupes and Gracey Mini Five curettes, without irrigation. The deepest interproximal site in each patient served as the experimental site. A single calibrated, blinded examiner recorded the clinical parameters at baseline, 1, 3 and 6 months. GCF was collected with paper points, and VEGF was measured by ELISA. CAL, PD and VEGF were analyzed by mixed MANOVA with Bonferroni correction. PI and GI were analyzed with the Kruskal-Wallis, Mann-Whitney, Friedman and Wilcoxon tests, and BoP with the chi-square, Cochran's Q and McNemar tests. Results: All 66 patients completed follow-up. The groups were comparable at baseline (p \> 0.05), and all improved significantly over time (p \< 0.001). Mean baseline CAL was similar in Groups I, II and III (5.36, 5.41 and 5.32 mm). At 6 months it had fallen to 3.86, 3.36 and 3.05 mm, giving mean gains of 1.50, 2.05 and 2.27 mm respectively. Both adjunct groups gained more attachment than the control from the first month onward, and CGF gained more than HA at 3 and 6 months (p = 0.03). Mean PD fell from 5.50, 5.36 and 5.41 mm at baseline to 3.82, 3.41 and 2.95 mm at 6 months, reductions of 1.68, 1.95 and 2.46 mm. CGF gave a greater PD reduction than HA at 3 months (p = 0.01) and 6 months (p = 0.002). GCF VEGF started at similar levels in all groups (about 1790-1820 pg/mL) and fell significantly at every interval. At 6 months it was 1341.40 pg/mL in Group I, 1264.82 pg/mL in Group II and 1182.66 pg/mL in Group III. The CGF group had the lowest levels at 3 and 6 months compared with HA (p = 0.01) and control (p = 0.001). PI and GI improved in all groups; PI was significantly better with CGF at 3 and 6 months, and GI with CGF at 3 months (p = 0.001), with no GI difference between groups at 6 months. BoP was present in 20 of 22 patients (90.9%) in each group at baseline. At 1 month it was present in 54.5%, 31.8% and 13.6% of patients in Groups I, II and III (p = 0.016), and in no patient at 3 and 6 months. Limitations: The study was carried out at a single centre, with a 6-month follow-up and one experimental site per patient. No radiographic or histological assessment was performed, so CAL gain reflects clinical repair through a long junctional epithelium rather than proven regeneration. The control group received no placebo, so the greater PI improvement in the adjunct groups may reflect performance bias. VEGF was first resampled at 1 month, after the early growth-factor release from CGF. Only healthy non-smokers aged 20-40 years were included. Conclusion: Adding HA gel or liquid CGF to MINST produced greater clinical and biochemical improvement than MINST alone over 6 months in stage II-III periodontitis. CGF was the most effective adjunct for CAL gain, PD reduction and lowering GCF VEGF.
Conditions
- Periodontitis
Interventions
Minimally invasive non-surgical therapy (MINST)Procedure
Description: Subgingival debridement following the MINST protocol (Nibali et al.), done under local anesthesia with 5× magnification loupes and Gracey Mini Five curettes (Hu-Friedy). A subpapillary approach preserves the papillae. Roots are cleaned to the base of the pocket without excessive root planing or gingival curettage, and the pocket is not irrigated, to keep the blood clot stable. All pockets deeper than 3 mm are treated in a single session, after a 4-week initial hygiene phase.
0.8% High-Molecular-Weight Hyaluronic Acid GelDevice
Immediately after MINST, 0.8% high-molecular-weight hyaluronic acid gel is injected into the pocket at the experimental site with a sterile syringe and blunt plastic needle until it overflows the gingival margin. The application is repeated 4 weeks later. Patients avoid eating and drinking for 1 hour and brushing the treated site for 24 hours.
Concentrated Growth Factor (CGF), autologousBiological
About 9 mL of the patient's venous blood is collected into sterile plastic tubes without anticoagulant or clot activator. The tubes are centrifuged in a Medifuge (Silfradent) with the alternating-speed CGF program (2700, 2400, 2700 and 3000 rpm; 692-855 × g). The upper liquid fraction is aspirated and, immediately after MINST and before it clots, injected into the pocket at the experimental site with a blunt needle until it overflows the gingival margin. The application is repeated 4 weeks later. No periodontal dressing is used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Attachment Level (CAL)Time frame: Baseline, 1 month, 3 months and 6 months after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Faculty of Dentistry, October 6 University
Giza, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.